Showing 5001-5010 of 8626 results for "".
- Phase 3 Study: Aclaris Therapeutics’ A-101 45% May Help Thwart Common Wartshttps://practicaldermatology.com/news/phase-3-study-aclaris-therapeutics-a-101-45-may-help-thwart-common-warts/2460198/Aclaris Therapeutics, Inc.’s A-101 45% Topical Solution (A-101 45%), an investigational new drug, for the potential treatment of common warts, performed well in its second Phase 3 clinical trial, THWART-1 (WART-301). A-101 45% met the primary and all secondary efficacy endpoints,
- Galderma Will Begin Seven New Clinical Studieshttps://practicaldermatology.com/news/galderma-will-begin-seven-new-clinical-studies/2460197/Galderma is initiating seven clinical studies that seek to support potential, new aesthetic indications including a tear trough indication for Restylane, a facial wrinkles indication for Sculptra Aesthetic as well as several studies supporting an investigational liquid neurotoxin and a Phase 2 st
- New Indication for Cellfina: Cleared for 5 Years of Benefit for Cellulitehttps://practicaldermatology.com/news/new-indication-for-cellfina-approval-for-5-years-of-benefit-for-cellulite/2460195/The FDA has cleared a new indication statement for Cellfina that shows the benefits of treatment last for five years, an increase from the previous three-year indication. Cellfina from Merz demonstrated five-year improvement in the appearance of cellulite on the buttocks and thighs of adult femal
- UCB Presents New Data for Cimzia, Investigational Bimekizumabhttps://practicaldermatology.com/news/ucb-presents-new-data-for-cimzia-investigational-bimekizumab/2460193/Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of Dermatology and Venereology congress (EADV) in Madrid. Cim
- Consumers Cite Dermatologists as Top Influencers of Cosmetic Procedure, Skin Care Choices: ASDShttps://practicaldermatology.com/news/consumers-site-dermatologists-as-top-influencers-of-cosmetic-procedure-skin-care-choices-asds/2460191/When it comes to consumer decisions on cosmetic procedures and skin care choices, dermatologists are the leading influencers, results of the 2019
- Dermira Shares Positive Data From Phase 2b Study of Lebrikizumab for Atopic Dermatitis at Fall Clinical Dermatology Conferencehttps://practicaldermatology.com/news/dermira-shares-positive-data-from-phase-2b-study-of-lebrikizumab-for-atopic-dermatitis-at-fall-clinical-dermatology-conference/2460190/Primary results from Dermira, Inc.'s Phase 2b dose-ranging study of lebrikizumab were presented during the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderat
- Lilly: New Data for Treatment of Complex Dermatological Conditions at EADV, Maui Derm NP+PAhttps://practicaldermatology.com/news/lilly-new-data-for-treatment-of-complex-dermatological-conditions-at-eadv-maui-derm-nppa/2460188/New data for Eli Lilly and Company’s Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab have been presented at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress in Madrid. The company says the research h
- Psoriasis Linked to Developing and Dying from Cancerhttps://practicaldermatology.com/news/psoriasis-linked-to-developing-and-dying-from-cancer/2460185/Psoriasis may increase the risk for certain cancers, according to a review of 58 studies published in JAMA Dermatology. Moreover, the risk of dying from certain site-specific cancers was elevated in those with severe psoriasis. Specifically, severe psoriasi
- Positive Top-line Results Seen in Pivotal Phase 3 Clinical Trial of StrataGraft Regenerative Tissue Deep Partial-thickness Thermal Burnshttps://practicaldermatology.com/news/positive-top-line-results-seen-in-pivotal-phase-3-clinical-trial-of-stratagraft-regenerative-tissue-deep-partial-thickness-thermal-burns/2460178/Mallinckrodt plc's pivotal Phase 3 clinical trial evaluating the efficacy and safety of a single application of StrataGraft regenerative tissue in the treatment of deep partial-thickness thermal burns met both primary endpoints. The pivotal open-label, controlled, randomized, multic
- Pediatric AD Takes Its Toll on Caregiver Emotional Wellbeinghttps://practicaldermatology.com/news/ad-takes-its-toll-on-caregiver-emotional-wellbeing/2460173/Family members and caregivers of children with atopic dermatitis (AD) may be at increased risk for anxiety and depression, according to new research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Researchers from the PHIUniversity Clinic of Dermatol